Drug intelligence / Profile preview

Ricimed

Development stage: Unknown
Lead developer: Fabentech
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ricimed is an antibody-based therapy developed by Fabentech, specifically utilizing polyclonal antibodies. It functions as an antidote for ricin poisoning, a severe and potentially fatal intoxication caused by the highly toxic natural substance, ricin. Ricimed works by targeting and neutralizing the ricin toxin before it can inflict irreversible cellular damage, thereby addressing a critical unmet medical need. The drug has received Marketing Authorisation in France, positioning it as a key component of European biodefence readiness against the biological threat of ricin poisoning.

Brand names: Ricimed

Targets

RTB (Ricin toxin B subunit)

Beyond the preview

Go deeper on Ricimed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ricimed.

Explore the full profile